A new trading day began on Monday, with Kyverna Therapeutics Inc (NASDAQ: KYTX) stock price down -8.65% from the previous day of trading, before settling in for the closing price of $3.99. KYTX’s price has ranged from $3.62 to $35.06 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -37.90%. Meanwhile, its annual earnings per share averaged 96.32%. With a float of $18.72 million, this company’s outstanding shares have now reached $43.17 million.
Let’s determine the extent of company efficiency that accounts for 96 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc (KYTX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kyverna Therapeutics Inc is 56.65%, while institutional ownership is 31.26%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc (KYTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 96.32% per share during the next fiscal year.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Trading Performance Indicators
Here are Kyverna Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.07, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.72 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc (KYTX)
Looking closely at Kyverna Therapeutics Inc (NASDAQ: KYTX), its last 5-days average volume was 0.23 million, which is a drop from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 29.35%. Additionally, its Average True Range was 0.40.
During the past 100 days, Kyverna Therapeutics Inc’s (KYTX) raw stochastic average was set at 2.00%, which indicates a significant decrease from 7.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.46% in the past 14 days, which was lower than the 86.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.77, while its 200-day Moving Average is $10.09. However, in the short run, Kyverna Therapeutics Inc’s stock first resistance to watch stands at $3.90. Second resistance stands at $4.15. The third major resistance level sits at $4.33. If the price goes on to break the first support level at $3.47, it is likely to go to the next support level at $3.29. Now, if the price goes above the second support level, the third support stands at $3.04.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Key Stats
With a market capitalization of 157.36 million, the company has a total of 43,172K Shares Outstanding. Currently, annual sales are 0 K while annual income is -60,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -34,490 K.
